Fig. 5
RCT001 efficiently inhibits RCC growth and synergizes with ICIs. RENCA cells were injected subcutaneously. Once the tumor reached 30 mm3, mice were divided into different groups: Control (n = 10), RCT001 alone (n = 10, 20 mg/kg), anti-PD-1 + anti-CTLA4 (n = 10, 100 μg each) and the combination of RCT001 + PD-1 + anti-CTLA4 (n = 10). a Tumor volume was measured each day. Results are expressed as mean ± sd. b Tumor weights at the end of the experiment. c Blood vessels were visualized and quantified by IHC for αSMA d Tumor-associated macrophages (TAMs, total population), M2 TAMs and M1 TAMs were evaluated by cytometry. e The specific mRNA markers of M2 TAMs (CCL17 and CCL22) and mRNA CXCR2 were determined by qPCR. f Tumor-associated neutrophils (TANs, total population) and mature TANs were evaluated by cytometry. g Intratumor dendritic cells (DCs, total population) and activated dendritic cells were evaluated by flow cytometry. h Intratumor natural killer (NKs, total population) and activated natural killer were evaluated by cytometry. i Intratumor T cells (total population) and CD4 + T, Activated CD4 + T were evaluated by flow cytometry. j Intratumor activated T cell specific mRNA marker (INFγ) mRNA was evaluated by qPCR. k Intratumor CD8 T, activated CD8 T and anergic CD8 T were evaluated by flow cytometry. l Intratumor anergic T cell specific mRNA marker (PD-L1) mRNA was evaluated by qPCR. Statistics were performed using the ANOVA test: *p < 0.01, **p < 0.01, *** p < 0.001